ADA: insulin-pump tx with threshold-suspend beneficial

ADA: insulin-pump tx with threshold-suspend beneficial
For patients with type 1 diabetes and documented nocturnal hypoglycemia, insulin-pump therapy with a threshold-suspend feature reduces nocturnal hypoglycemia over a three-month period, according to a study published online June 22 in the New England Journal of Medicine to coincide with presentation at the annual meeting of the American Diabetes Association, held from June 21 to 25 in Chicago.

(HealthDay)—For patients with type 1 diabetes and documented nocturnal hypoglycemia, insulin-pump therapy with a threshold-suspend feature reduces nocturnal hypoglycemia over a three-month period, according to a study published online June 22 in the New England Journal of Medicine to coincide with presentation at the annual meeting of the American Diabetes Association, held from June 21 to 25 in Chicago.

Richard M. Bergenstal, M.D., from the International Diabetes Center at Park Nicollet in Minneapolis, and colleagues compared sensor-augmented insulin-pump therapy with and without a threshold-suspend feature in 247 patients with and nocturnal hypoglycemia. Participants were randomized to receive sensor-augmented insulin-pump therapy with the threshold-suspend feature (121 patients) or standard sensor-augmented insulin-pump therapy (126 patients) for three months.

The researchers observed similar changes in glycated hemoglobin values in both groups. For nocturnal hypoglycemic events, the mean area under the curve was 37.5 percent lower in the threshold-suspend versus the control group. In the threshold-suspend group, nocturnal hypoglycemic events occurred 31.8 percent less frequently than in the control group. In the threshold-suspend group, the percentages of nocturnal sensor glucose values of less than 50 mg/dL, 50 to less than 60 mg/dL, and 60 to less than 70 mg/dL were significantly lower. Four patients experienced a severe hypoglycemic event, all in the control group.

"This study showed that over a three-month period the use of sensor-augmented insulin-pump therapy with the threshold-suspend feature reduced , without increasing glycated hemoglobin values," the authors write.

The study was funded by Medtronic MiniMed, manufacturer of the pumps used in the study.


Explore further

Insulin LY2605541 tops glargine for glycemic control in T1DM

More information: Abstract
Full Text
More Information
Journal information: New England Journal of Medicine

Health News Copyright © 2013 HealthDay. All rights reserved.

Citation: ADA: insulin-pump tx with threshold-suspend beneficial (2013, June 24) retrieved 17 October 2019 from https://medicalxpress.com/news/2013-06-ada-insulin-pump-tx-threshold-suspend-beneficial.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more